Display options
Cite
Emilien G. BTS-67582 (Knoll Pharmaceuticals Co). IDrugs. 1999;2(4):355-9
Emilien, G. (1999). BTS-67582 (Knoll Pharmaceuticals Co). IDrugs : the investigational drugs journal, 2(4), 355-9.
Emilien, G. "BTS-67582 (Knoll Pharmaceuticals Co)." IDrugs : the investigational drugs journal vol. 2,4 (1999): 355-9.
Emilien G. BTS-67582 (Knoll Pharmaceuticals Co). IDrugs. 1999 Apr;2(4):355-9. PMID: 16158354.
Copy Download .nbib Format: NLM
Share it on

IDrugs. 1999 Apr;2(4):355-9.

BTS-67582 (Knoll Pharmaceuticals Co).

IDrugs : the investigational drugs journal

G Emilien

Affiliations

  1. Department of Pharmacology, Universite Catholique de Louvain, Cliniques Universitaires Saint Luc, Brussels, Belgium. [email protected]

PMID: 16158354

Abstract

BTS-67582, a morpholinoguanidine, is a potassium channel blocker in phase II trials by Knoll in the US, the UK and France for the treatment of diabetes. Knoll acquired the drug as part of the 1995 purchase of the pharmaceutical operations of Boots by its parent company BASF. Clinical studies using a double-blind, placebo-controlled, multicenter design have been conducted with non-insulin dependent diabetes mellitus (NIDDM) patients. Results showed that BTS-67582 was well tolerated and effective when used in a twice-daily dosing regimen. BTS-67582 and analogs are claimed in British patent GB-02226562-A, 'Hypoglycemic amidines and guanidines', assigned to the Boots Company plc.

Publication Types